ArticleBlood advances2024

Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.

Jennifer N Brudno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.